Lenalidomide

small molecule

Identifier: CI-DRUG-00000335
Entity page: /drug/lenalidomide ↗
Edges: 1,191

Neighbours: 20 cancers4 genes1 variants10 trials15 approvals
Drawn: 50 of 50 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lenalidomide approved for …APPROVED_FOR26 of 15
→ approved for	Chronic Lymphocytic Leukemiahematologic_malignancy	supports	FDA ORIG	Chronic Lymphocytic Leukemia	1	Regulatory	openfda	graph →
→ approved for	Marginal Zone Lymphomahematologic_malignancy	supports

→ approved for

EMA · EU · 2021Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

EMA (EU) · approved · 2021-02-11 · Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

EMA (EU) · approved · 2021-02-11 · Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly di…

—

approved

not mapped

Regulatory

ema

open ↗

Lenalidomide predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	CRBN Mutationother	resistance	C	Multiple Myeloma	1	Curated	civic	graph →

Lenalidomide targets …TARGETS4 of 4
→ targets	RBX1	—	INHIBITOR\|MODULATOR	—	1	Curated	chembl	graph →
→ targets	CUL4A	—	INHIBITOR\|MODULATOR	—	1	Curated	chembl	graph →
→ targets	CRBN	—	INHIBITOR\|MODULATOR	—	1	Curated	chembl	graph →
→ targets	DDB1	—	INHIBITOR\|MODULATOR	—	1	Curated	chembl	graph →

Lenalidomide investigated for …INVESTIGATED_FOR15 of 63show all (up to 200)
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	4	Follicular Lymphoma	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	unknown	4	Multiple Myeloma	1	Curated	chembl	graph →
→ investigated for	Myelodysplastic Syndromehematologic_malignancy	unknown	4	Myelodysplastic Syndrome	1	Curated	chembl	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	4	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	supports	C	Multiple Myeloma	1	Curated	civic	graph →
→ investigated for	Plasma Cell Neoplasmhematologic_malignancy	unknown	3	Plasma Cell Neoplasm	1	Curated	chembl	graph →
→ investigated for	Plasmacytomahematologic_malignancy	unknown	3	Plasmacytoma	1	Curated	chembl	graph →
→ investigated for	Smoldering Multiple Myelomahematologic_malignancy	unknown	3	Smoldering Multiple Myeloma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	3	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	3	Melanoma	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	3	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	3	Acute Myeloid Leukemia	1	Curated	chembl	graph →
→ investigated for	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissuehematologic_malignancy	unknown	3	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	3	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Lymphoid Leukemiahematologic_malignancy	unknown	2	Lymphoid Leukemia	1	Curated	chembl	graph →

Lenalidomide investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 245show all (up to 200)
→ investigated in trials for	Multiple Myelomahematologic_malignancy 372 trials (126 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	372	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 57 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Large B-Cell Lymphoma 56 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 47 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Lymphomahematologic_malignancy 44 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Lymphoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 42 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 36 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 32 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Marginal Zone Lymphomahematologic_malignancy 29 trials (13 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Marginal Zone Lymphoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 25 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 24 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic Syndromehematologic_malignancy 22 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Smoldering Multiple Myelomahematologic_malignancy 17 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Smoldering Multiple Myeloma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 1 Follicular Lymphomahematologic_malignancy 15 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 1 Follicular Lymphoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 2 Follicular Lymphoma 15 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 2 Follicular Lymphoma	15	Observed	clinicaltrials	graph →

Lenalidomide studied in …STUDIED_INderived10 of 863show all (up to 200)
→ studied in	NCT02180711Phase 1/Phase 2 · active not recruiting Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma · 863 trials list this drug (249 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · 863 trials list this drug (249 active)	—	—	Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · 863 trials list this drug (249 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma,Smoldering Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · 863 trials list this drug (249 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02538198Phase 2 · active not recruiting Lenalidomide Maintenance in Plasma Cell Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02619682Phase 2 · completed Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma,Transplant-Related Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · 863 trials list this drug (249 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths